FINWIRES · TerminalLIVE
FINWIRES

Centerra Gold社、第1四半期の売上高と調整後利益が増加、2026年の生産見通しを発表

By

-- Centerra Gold(CG.TO、CGAU)は、水曜日の取引終了後、第1四半期の売上高と調整後利益が前年同期比で増加したと発表した。 同社によると、ほとんどの一時的な項目を除いた調整後利益は、前年同期の2,640万ドル(1株当たり0.13ドル)から8,820万ドル(1株当たり0.44ドル)に増加した。FactSetは1株当たり0.43ドルを予想していた。 売上高は前年同期の2億9,950万ドルから62%増の4億8,470万ドルとなった。FactSetは3億7,350万ドルを予想していた。 金生産量は68,001オンス、銅生産量は1,420万ポンドだった。金販売量は72,935オンス、平均販売価格は1オンス当たり4,172ドル、銅販売量は1,490万ポンド、平均販売価格は1ポンド当たり4.48ドルだった。同社によると、これらの価格にはロイヤル・ゴールド社とのマウント・ミリガン鉱山におけるストリーミング契約の影響が含まれている。 「今四半期、当社の財務状況は強化され、現金残高は5億4300万ドルに増加しました。これは、社内成長パイプラインへの投資を継続し、ランゲロス鉱山の運転資金を積み増し、さらに自社株買いと配当を通じて株主に3300万ドルを還元したことによって達成されました」と、ポール・トモリー最高経営責任者(CEO)は述べた。 同社は2026年の金生産量を25万~28万オンス、銅生産量を5000万~6000万ポンドと見込んでいる。 センターラ社の株価はトロント証券取引所で0.75カナダドル安の23.90カナダドルで取引を終えた。

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ